These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22155915)

  • 1. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
    Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
    Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.
    De Pablo C; Orden S; Apostolova N; Blanquer A; Esplugues JV; Alvarez A
    AIDS; 2010 Jun; 24(9):1259-66. PubMed ID: 20453628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
    Wohl DA; Arnoczy G; Fichtenbaum CJ; Campbell T; Taiwo B; Hicks C; McComsey GA; Koletar S; Sax P; Tebas P; Ha B; Massengale K; Walsh K; Stein JH
    Antivir Ther; 2014; 19(2):141-7. PubMed ID: 23985706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agents. Trying times for tenofovir and abacavir.
    TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
    De Pablo C; Orden S; Calatayud S; Martí-Cabrera M; Esplugues JV; Alvarez A
    Antivir Ther; 2012; 17(8):1615-9. PubMed ID: 22954798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
    Padilla S; Masiá M; García N; Jarrin I; Tormo C; Gutiérrez F
    BMC Infect Dis; 2011 Feb; 11():40. PubMed ID: 21294867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
    Delaugerre C; Roudiere L; Peytavin G; Rouzioux C; Viard JP; Chaix ML
    J Clin Virol; 2005 Mar; 32(3):241-4. PubMed ID: 15722030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
    [No Abstract]   [Full Text] [Related]  

  • 19. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
    Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
    AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.